GlassScriptPhysician profile
Ines Rodriguez
NPI 1659609410
$1,546.18
in general payments reported to CMS, 2019-2025
19 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $580 · 2023: $215 · 2024: $139 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.46 | 2021-2025 | Tagrisso, Airsupra |
| Genentech USA, INC. | $309.47 | 2021-2022 | |
| Novo Nordisk INC | $159.70 | 2022-2025 | Rybelsus, Ozempic |
| Beigene USA, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $99.99 | 2021 | |
| Sanofi Pasteur INC. | $73.95 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $40.80 | 2025 | Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $39.38 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $36.97 | 2023-2024 | Xarelto |
| Amgen INC. | $35.35 | 2024 | Repatha, Otezla |
| Mylan Pharmaceuticals INC. | $30.80 | 2022 | |
| Lilly USA, LLC | $30.58 | 2024-2025 | Jardiance |
| Pfizer INC. | $22.40 | 2025 | |
| Exact Sciences Corporation | $19.66 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.51 | 2025 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $16.32 | 2025 | Gemtesa |
| Phadia US INC. | $15.45 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $13.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ines Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.